



Onxeo's shares transferred to Compartment B on Euronext Paris

Paris (France), Copenhagen (Denmark), January 26, 2015 – Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announces that its shares will be transferred from Compartment C to Compartment B of the NYSE Euronext Paris with effect from January 28, 2015.

According to the regulations of NYSE Euronext, compartment changes are made annually on the basis of the market capitalization of the last 60 trading days of the year. Compartment B consists of listed companies with a market capitalization of between €150 million and €1 billion.

The transfer comes a few weeks after the selection of Onxeo to enter the EnterNext© PEA-PME 150, a benchmark index launched in November 2014 in response to the industry's demand for new benchmarks.

“The transfer of our shares to Compartment B is a key event showing the progression of our market value. After a successful merger in 2014, Onxeo now relies on strong fundamentals: 3 products in an advanced clinical stage, all positioned on dynamic markets in the orphan oncology field, and on an experienced team who already registered 3 products in the US and Europe, today commercialized by our partners. The company has also strengthened its own funds with a significant capital increase in December 2014. These assets and our reinforced market visibility should increase our attractiveness to international investors in the next months”, comments Nicolas Fellmann, CFO of Onxeo.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to “make the difference”. The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key products at advanced development stage are:

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma

Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results

Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the

Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website (www.onxeo.com).

Contacts :

Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP
caroline@alizerp.com / scolin@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62